Hemab Therapeutics Holdings, Inc. cotiza a 30.39 USD y tiene una capitalización bursátil de $1.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase…
| Periodo | 2026-11 | 2026-08 | 2026-08 |
|---|---|---|---|
| Real | — | — | $-0.80 |
| Estimado | $-0.50 | $-0.82 | $-0.82 |
| Sorpresa | — | — | +2.4% |
| Métrica | COAG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 18.03 | 2.84 | +15.19 |
| Debt / Equity | — | 0.28 | — |